[Has the era of warfarin terminated?].
Warfarin has for a long time been considered the "gold standard" of oral anticoagulant therapy. Positive effects of this agent are unambiguously supported by accumulated evidence-based data convincingly confirming a decrease in the risk for thrombolytic complications in patients with many diseases of the cardiovascular system: atrial fibrillation, thrombosis of deep veins of extremities, pulmonary artery thromboembolism. However, warfarin has a series of disadvantages complicating its practical application: the necessity of individual adjustment of the dose to maintain the International Normalized Ratio (INR) within the limits of the target values, clinically significant interactions with other drugs and foodstuffs. In this connection, the advent of new oral anticoagulants such as dabigatran, rivaroxaban, and apixaban is associated with great hopes concerning increased efficiency and safety of anticoagulant therapy. However, while the results of large-scale clinical trials are promising, the data on using these agents in real clinical practice suggest that prescription and administration of new oral anticoagulants should be approached with great caution, thoroughly weighing potential risks and benefits. Therefore, switching over the patients with the already adjusted dosage of warfarin and stable values of the INR to new drugs seems hardly advisable.